Neurogene Inc. (NGNE) has released an update.
Neurogene Inc. has announced an expansion of its Phase 1/2 clinical trial for the gene therapy NGN-401, aimed at treating Rett syndrome in female pediatric patients. The trial’s Cohort 1 capacity has increased and will now expedite patient enrollment by removing staggered dosing, with completion expected in the second half of 2024. Additionally, a higher dose Cohort 2 has been introduced, which includes a precautionary immunosuppression regimen to mitigate potential immune responses.
For further insights into NGNE stock, check out TipRanks’ Stock Analysis page.
